Clinical trials: Body Weight Control
Obesity
The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity
This is a 24-week study to evaluate the effects of two fixed-dose combinations of leucine and sildenafil or two fixed-dose combinations of leucine, sildenafil and metformin compared to placebo.
- Trial name
- NCT03364335
- Testing
- Leu Sil 1.0mg, Leu Sil 4.0mg, Leu Met Sil 1.0mg
- Where
- 15 sites in United States
- Volunteers
- 267 people
- Sponsor
- NuSirt Biopharma
Overweight, Obesity
Electrical Vestibular Nerve Stimulation (VeNS) Compared to Sham Control as a Means of Reducing Excess Body Weight
A randomized, double blind sham controlled clinical trial to evaluate the efficacy of vestibular nerve stimulation (VeNS), together with a lifestyle modification program, compared to a sham control with a lifestyle modification…
- Conditions
- Overweight, Obesity, Overweight and Obesity, Overweight or Obesity
- Trial name
- NCT04110717
- Testing
- Vestal Device, Control Device, Hypocaloric Diet
- Where
- Ireland
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Neurovalens Ltd.
Healthy Volunteers, Obesity
Phase 1 Clinical Study of MWN117 Injection in Healthy Participants and Participants With Obesity
This study is a randomized, double-blind, placebo-controlled, single-dose, dose-escalation Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MWN117 injection in healthy and…
- Trial name
- NCT07824804
- Testing
- MWN117
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Obesity, Weight Loss
Study to Examine the Longer-Term Efficacy and Safety of Sibutramine Hydrochloride in Obese Subjects
The study was designed to evaluate the long term efficacy and safety of Meridia 15 mg daily in obese subjects.
- Trial name
- NCT00645255
- Volunteers
- 466 people
- Sponsor
- Abbott
Overweight or Obesity
Efficacy and Safety of SYH2069 Injection in Obese Participants Without Diabetes.
To evaluate the efficacy and safety of SYH2069 injection compared with placebo in obese Non-diabetic Participants after 28 weeks of treatment.
- Trial name
- NCT07803991
- Testing
- SYH2069 Injection
- Where
- China
- Volunteers
- 360 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Type 2 Diabetes, Cardiovascular Risk
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
This study is being conducted to find out how well zenagamtide works and how safe it is compared to insulin glargine in participants with type 2 diabetes who are at higher risk of heart and blood vessel problems and are already…
- Trial name
- AMBITION 7 (NCT07797335)
- Testing
- Zenagamtide, Insulin glargine U-100
- Where
- 330 sites in United States, Argentina and 14 more
- Volunteers
- 1,778 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Study on How NNC0174-1213 Works in People With Overweight or Obesity.
This study is testing a new study medicine to treat people living with overweight or obesity. The aim of this study is to see if the medicine is safe, how it works in human body, and what human body does to the study medicine.
- Trial name
- NCT06719011
- Testing
- NNC0174-1213 A, Cagrilintide B
- Where
- 2 sites in United States
- Volunteers
- 178 people
- Sponsor
- Novo Nordisk A/S
Overweight and Obesity, Dyslipoproteinemia
Effect of Weight Management Programs on Cardiometabolic Risk Profile in Overweight Women
Aim of this prospective randomized study was to evaluate whether a diet with meal replacements can be as effective as a conventional energy-restricted modified diet on weight loss, body composition and cardiometabolic risk…
- Trial name
- FM-01 (NCT03109834)
- Testing
- Meal replacement (MR), Control (C), Verum
- Volunteers
- 105 people
- Sponsor
- Bonn Education Association for Dietetics r.A., Cologne, Germany
Obesity, Overweight
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus.
- Conditions
- Obesity, Overweight, Diabetes Mellitus, Type 2
- Trial name
- NCT07684144
- Testing
- Maridebart Cafraglutide
- Where
- 45 sites in United States, Canada and 3 more
- Volunteers
- 950 people
- Sponsor
- Amgen
Overweight or Obesity
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-4729 injection in healthy subjects.
- Trial name
- NCT06762600
- Testing
- HRS-4729 injection, HRS9531 injection, Acetaminophen
- Where
- China
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Obesity, Hypertension
Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension.
The purpose of this study is to determine the efficacy of candesartan, once daily (QD), combined with hydrochlorothiazide to lower blood pressure in insulin-resistant, obese patients with hypertension.
- Trial name
- NCT00775814
- Testing
- Candesartan and Hydrochlorothiazide, Hydrochlorothiazide (HCT)
- Where
- 24 sites in Germany
- Volunteers
- 188 people
- Sponsor
- Takeda
Overweight, Obesity
Weight and Metabolic Management Study
The goal of this clinical trial is to learn whether elénzia CONTROL®, a nutritional supplement, can support weight management in adults who have either never used GLP-1 weight-loss medications or have recently stopped using them.
- Conditions
- Overweight, Obesity, Weight Maintenance
- Trial name
- WMMS (NCT07789223)
- Testing
- elénzia CONTROL®
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Elenzia
Overweight, Obesity
Weight Loss in Adults Using Semaglutide (Real-world Study)
The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.
- Trial name
- NCT07627074
- Testing
- Semaglutide
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 237,211 people
- Sponsor
- Novo Nordisk A/S
Cachexia
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of GSK2881078 in Single and Repeat Doses
This study is the first administration of GSK2881078 to humans. The intention of this study is to provide sufficient confidence in the safety of the molecule to inform progression to further repeat dose and proof of concept…
- Trial name
- NCT02045940
- Testing
- GSK2881078
- Where
- 2 sites in United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Overweight, Obesity
Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity
This study will look at participants' body weight from the start to the end of the study. The study will last for about 1½ years.
- Trial name
- STEP 8 (NCT04074161)
- Testing
- Semaglutide, Liraglutide
- Where
- 19 sites in United States
- Volunteers
- 338 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight.
- Trial name
- TRIUMPH-9 (NCT07357415)
- Testing
- Retatrutide
- Where
- 35 sites in United States, Argentina and 1 more
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
Metabolism and Nutrition Disorder, Obesity
A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity
This trial is conducted in the United States of America. The aim of the trial is to investigate Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects being overweight or with obesity
- Trial name
- NCT02835235
- Testing
- NNC9204-0530
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Novo Nordisk A/S
Overweight, Diabetes Mellitus Type 2 in Obese
Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses of P11187
Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P11187 It will be conducted in three parts, as described below: Part I will be the Single…
- Trial name
- NCT01874366
- Testing
- P11187
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Piramal Enterprises Limited
Obesity, Eating Disorders
Efficacy and Safety of Rimonabant on Weight Loss and Frequency of Binge Episodes in Obese Patients
The primary objective is to assess the effect of rimonabant compared to placebo on weight loss over a period of 6 months when prescribed with a mild hypocaloric diet in obese patients with binge eating disorder.
- Trial name
- NCT00481975
- Testing
- rimonabant (SR141716)
- Where
- 7 sites in United States, Finland and 5 more
- Volunteers
- 289 people
- Sponsor
- Sanofi
Obesity, Overweight
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA) being developed for chronic weight…
- Conditions
- Obesity, Overweight, Type 2 Diabetes Mellitus (T2DM)
- Trial name
- NCT07670416
- Testing
- Enicepatide
- Where
- 21 sites in China
- Volunteers
- 300 people
- Sponsor
- Hoffmann-La Roche